Literature DB >> 11216946

Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

P H Frissen, J de Vries, H M Weigel, K Brinkman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216946     DOI: 10.1097/00002030-200101260-00027

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

Review 1.  Antiretroviral therapy: current drugs.

Authors:  Alice K Pau; Jomy M George
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

Review 2.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

3.  HLA-B*5701 testing to predict abacavir hypersensitivity.

Authors:  Joseph D Ma; Kelly C Lee; Grace M Kuo
Journal:  PLoS Curr       Date:  2010-12-07

4.  Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

Authors:  Ward De Spiegelaere; Jan Philippé; Karen Vervisch; Chris Verhofstede; Eva Malatinkova; Maja Kiselinova; Wim Trypsteen; Pawel Bonczkowski; Dirk Vogelaers; Steven Callens; Jean Ruelle; Kabamba Kabeya; Stephane De Wit; Petra Van Acker; Vicky Van Sandt; Marie-Paule Emonds; Paul Coucke; Erica Sermijn; Linos Vandekerckhove
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

5.  The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.

Authors:  Laura Stocchi; Raffaella Cascella; Stefania Zampatti; Antonella Pirazzoli; Giuseppe Novelli; Emiliano Giardina
Journal:  Curr Genomics       Date:  2012-06       Impact factor: 2.236

6.  Antiretroviral Therapy-associated Serious and Life-threatening Toxicities.

Authors:  Alice K. Pau
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.663

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.